bioAffinity to present CyPath Lung data showing Stage 1A detection in challenging cases at ACS NLCRT Dec 8

bioAffinity Technologies, Inc.

CyPath Lung identified Stage 1A lung cancer in three patients with atypical presentations.
Poster session at American Cancer Society National Lung Cancer Roundtable on Dec 8, 2025, 2:35-3:15 p.m. ET.
Chief Medical Officer Gordon Downie presenting cases from Titus Regional Hospital Lung Nodule Clinic.
Test uses flow cytometry and AI on sputum; prior study showed 92% sensitivity and 87% specificity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.